Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study

Ingrid S. van Maurik*, Stephanie J. Vos, Isabelle Bos, Femke H. Bouwman, Charlotte E. Teunissen, Philip Scheltens, Frederik Barkhof, Lutz Frolich, Johannes Kornhuber, Jens Wiftfang, Wolfgang Maier, Oliver Peters, Eckart ROther, Flavio Nobili, Giovanni B. Frisoni, Luiza Spiru, Yvonne Freund-Levi, Asa K. Wallin, Harald Hampel, Hilkka SoininenMagda Tsolaki, Frans Verhey, Iwona Kloszewska, Patrizia Mecocci, Bruno Vellas, Simon Lovestone, Samantha Gailuzzi, Sanna-Kaisa Herukka, Isabel Santana, Ines Baldeiras, Alexandre de Mendonca, Dina Silva, Gael Chetelat, Stephanie Egret, Sebastian Palmqvist, Oskar Hansson, Pieter Jelle Visser, Johannes Berkhof, Wiesje M. van der Flier, Alzheimer's Disease Neuroimaging Initiative

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

46 Citations (Web of Science)
42 Downloads (Pure)


Background Biomarker-based risk predictions of dementia in people with mild cognitive impairment are highly relevant for care planning and to select patients for treatment when disease-modifying drugs become available. We aimed to establish robust prediction models of disease progression in people at risk of dementia.

Methods In this modelling study, we included people with mild cognitive impairment (MCI) from single-centre and multicentre cohorts in Europe and North America: the European Medical Information Framework for Alzheimer's Disease (EMIF-AD; n=883), Alzheimer's Disease Neuroimaging Initiative (ADNI; n=829), Amsterdam Dementia Cohort (ADC; n=666), and the Swedish BioFINDER study (n=233). Inclusion criteria were a baseline diagnosis of MCI, at least 6 months of follow-up, and availability of a baseline Mini-Mental State Examination (MMSE) and MRI or CSF biomarker assessment. The primary endpoint was clinical progression to any type of dementia. We evaluated performance of previously developed risk prediction models-a demographics model, a hippocampal volume model, and a CSF biomarkers model-by evaluating them across cohorts, incorporating different biomarker measurement methods, and determining prognostic performance with Harrell's C statistic. We then updated the models by re-estimating parameters with and without centre-specific effects and evaluated model calibration by comparing observed and expected survival. Finally, we constructed a model combining markers for amyloid deposition, tauopathy, and neurodegeneration (ATN), in accordance with the National Institute on Aging and Alzheimer's Association research framework.

Findings We included all 2611 individuals with MCI in the four cohorts, 1007 (39%) of whom progressed to dementia. The validated demographics model (Harrell's C 0.62, 95% CI 0.59-0.65), validated hippocampal volume model (0.67, 0.62-0.72), and updated CSF biomarkers model (0.72, 0.68-0.74) had adequate prognostic performance across cohorts and were well calibrated. The newly constructed ATN model had the highest performance (0.74, 0.71-0.76).

Interpretation We generated risk models that are robust across cohorts, which adds to their potential clinical applicability. The models could aid clinicians in the interpretation of CSF biomarker and hippocampal volume results in individuals with MCI, and help research and clinical settings to prepare for a future of precision medicine in Alzheimer's disease. Future research should focus on the clinical utility of the models, particularly if their use affects participants' understanding, emotional wellbeing, and behaviour. Copyright (C) 2019 Elsevier Ltd. All rights reserved.

Original languageEnglish
Pages (from-to)1034-1044
Number of pages11
JournalLancet Neurology
Issue number11
Publication statusPublished - Nov 2019



Cite this